Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.71 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.71 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.71 |
| ▸ | F10 | P00742 | 3/20 | 0.63 |
| ▸ | F2 | P00734 | 6/20 | 0.54 |
| ▸ | C1S | P09871 | 1/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3666539 | 0.98 | LOXL2 (0.96) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL8542393 | 0.83 | PRSS1 (1.00) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL24358796 | 0.83 | PRSS1 (0.71) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL1696803 | 0.82 | PRSS1 (0.69) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL14714355 | 0.82 | PRSS1 (0.69) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL19527023 | 0.82 | LOXL2 (0.69) | LOXL2PRSS1PRSS2PRSS3F10 | |
| Guanidine SCHEMBL29065391 | 0.80 | LOXL2 (0.67) | LOXL2F10ENPP2 | |
| SCHEMBL24358735 | 0.80 | PRSS1 (0.67) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL15547311 | 0.79 | PRSS1 (0.70) | LOXL2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL509423 | 0.79 | LOXL2 (0.66) | LOXL2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3466961-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Li, Min (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| CN-102757737-A | Pressure-sensitive adhesive sheet and method for producing the same | NITTO DENKO CORP | 2012-10-31 | — | — | CN | disclosed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | MALLE GERARD | 2009-08-06 | — | — | US | disclosed |
| CN-101500594-A | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity | SIRION THERAPEUTICS INC (US) | 2009-08-05 | — | — | CN | disclosed |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | L'OREAL S.A. | 2009-06-04 | — | — | US | disclosed |
| US-20090110720-A1 | Use of compounds for the prevention of drug-induced cell toxicity | RECEPTICON APS (DK) | 2009-04-30 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | disclosed |
| WO-2004080970-A1 | NOVEL BICYCLIC AROMATIC COMPOUNDS, THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-23 | — | — | WO | disclosed |
| EP-1206444-A1 | COMPOUNDS THAT INHIBIT TRYPTASE ACTIVITY | Morphochem AG (DE) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001014320-A1 | COMPOUNDS THAT INHIBIT TRYPTASE ACTIVITY | MORPHOCHEM AG (DE) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090110720-A1 | Use of compounds for the prevention of drug-induced cell toxicity | SLC47A1, SLC10A6, SLC47A2 | LOXL2 1785/4885PRSS1 3063/4885PRSS2 3034/4885 |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | KRT18, INMT, INHA | LOXL2 2205/4885PRSS1 3478/4885PRSS2 3242/4885 |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | KRT18, KIT, PRDM7 | LOXL2 3405/4885PRSS1 4314/4885PRSS2 3742/4885 |
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | F12, F2, F11 | LOXL2 2651/4885PRSS1 182/4885PRSS2 638/4885 |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | LOXL2 741/4885PRSS1 2482/4885PRSS2 3346/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | LOXL2 2890/4885PRSS1 4545/4885PRSS2 4251/4885 |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | BHMT, KRT18, INMT | LOXL2 1760/4885PRSS1 2914/4885PRSS2 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.